# Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

> **NCT04077957** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Ankylosing Spondylitis
- Spondyloarthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Sulfasalazine
- **DRUG:** Hydroxychloroquine
- **DRUG:** Etanercept (50mg per week, for 4 weeks)
- **DRUG:** Etanercept (50mg per week, for 2 weeks)
- **DRUG:** Etanercept (50mg per week)

## Key facts

- **NCT ID:** NCT04077957
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-07
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-07-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077957, "Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04077957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*